Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) Research & Development (2020 - 2025)

Rapid Micro Biosystems' Research & Development history spans 6 years, with the latest figure at $3.5 million for Q3 2025.

  • For Q3 2025, Research & Development fell 2.22% year-over-year to $3.5 million; the TTM value through Sep 2025 reached $13.8 million, down 5.02%, while the annual FY2024 figure was $14.6 million, 13.86% up from the prior year.
  • Research & Development for Q3 2025 was $3.5 million at Rapid Micro Biosystems, up from $3.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.8 million in Q1 2024 and bottomed at $2.1 million in Q1 2021.
  • The 5-year median for Research & Development is $3.2 million (2023), against an average of $3.2 million.
  • The largest annual shift saw Research & Development skyrocketed 87.86% in 2021 before it dropped 13.73% in 2025.
  • A 5-year view of Research & Development shows it stood at $2.9 million in 2021, then increased by 19.19% to $3.4 million in 2022, then decreased by 2.5% to $3.3 million in 2023, then rose by 2.53% to $3.4 million in 2024, then increased by 3.73% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Research & Development are $3.5 million (Q3 2025), $3.2 million (Q2 2025), and $3.6 million (Q1 2025).